Crossmark

The impact of R353Q genetic polymorphism in coagulation factor VII on the initial anticoagulant effect exerted by warfarin

Crossref DOI link: https://doi.org/10.1007/s00228-018-2594-2

Published Online: 2018-11-09

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shaul, Chanan

Blotnick, Simcha

Deutsch, Liat

Rosenberg, Gilad

Caraco, Yoseph https://orcid.org/0000-0002-7959-2517
Funding

Funding for this research was provided by:

United States - Israel Binational Science Foundation (2003229)

Israel Science Foundation (789-04)
License Information

Text and Data Mining valid from 2018-11-09
More Information

Article History

Received: 19 July 2018

Accepted: 30 October 2018

First Online: 9 November 2018

Compliance with ethical standards

:

: Chanan Shaul declares no conflicts of interest.Simcha Blotnick declares no conflicts of interest.Liat Mlynarsky declares no conflicts of interest.Gilad Rosenberg was an employee of D-Pharm. Ltd. at the time of study conduct. D-Pharm. Ltd. sponsored the original study that investigated possible interaction between DP-b99 and warfarin (publication # 23 in the reference list).Yoseph Caraco declares no conflicts of interest.